Symbols / VTGN
VTGN Chart
About
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder. It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase II clinical trial for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial to treat loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. In addition, the company's clinical-stage pipeline consists of intranasal product candidates comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 22.08M |
| Enterprise Value | -38.26M | Income | -67.05M | Sales | 789.00K |
| Book/sh | 1.28 | Cash/sh | 1.56 | Dividend Yield | — |
| Payout | 0.00% | Employees | 59 | IPO | — |
| P/E | — | Forward P/E | -0.49 | PEG | — |
| P/S | 27.99 | P/B | 0.43 | P/C | — |
| EV/EBITDA | 0.55 | EV/Sales | -48.49 | Quick Ratio | 4.57 |
| Current Ratio | 4.67 | Debt/Eq | 2.80 | LT Debt/Eq | — |
| EPS (ttm) | -1.90 | EPS next Y | -1.13 | EPS Growth | — |
| Revenue Growth | 29.50% | Earnings | 2026-02-12 | ROA | -55.53% |
| ROE | -101.55% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -64.51% | Profit Margin | 0.00% | Shs Outstand | 39.62M |
| Shs Float | 33.78M | Short Float | 7.36% | Short Ratio | 1.46 |
| Short Interest | — | 52W High | 5.14 | 52W Low | 0.43 |
| Beta | 0.29 | Avg Volume | 2.88M | Volume | 313.50K |
| Target Price | $0.97 | Recom | Hold | Prev Close | $0.55 |
| Price | $0.56 | Change | 1.20% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$0.97
Mean price target
2. Current target
$0.56
Latest analyst target
3. DCF / Fair value
$-16.43
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.56
Low
$0.90
High
$1.00
Mean
$0.97
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-17 | down | William Blair | Outperform → Market Perform | — |
| 2025-12-17 | down | Maxim Group | Buy → Hold | — |
| 2025-12-17 | down | Jefferies | Buy → Hold | $1 |
| 2023-12-07 | up | Jefferies | Hold → Buy | $15 |
| 2023-11-14 | init | Stifel | — → Buy | $12 |
| 2023-09-05 | main | Maxim Group | Buy → Buy | $30 |
| 2023-08-07 | up | Maxim Group | Hold → Buy | $30 |
- Vistagen CEO to give corporate overview at TD Cowen healthcare event - Stock Titan Wed, 25 Feb 2026 13
- Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 16, 2026 in Vistagen Lawsuit - VTGN - Morningstar Wed, 25 Feb 2026 14
- VTGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026 - PR Newswire Sat, 21 Feb 2026 12
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN - ChartMill ue, 24 Feb 2026 20
- SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire ue, 24 Feb 2026 13
- Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) - March 16, 2026 Deadline to Join - Contact The Gross Law Firm (2026-02-24) - Seeking Alpha ue, 24 Feb 2026 14
- VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance hu, 12 Feb 2026 08
- Shareholders that lost money on Vistagen Therapeutics, Inc.(VTGN) Urged to Join Class Action - Contact The Gross Law Firm to Learn More - Barchart.com hu, 19 Feb 2026 14
- Is Vistagen Therapeutics Stock Built to Withstand More Downside? - Trefis Sun, 21 Dec 2025 08
- Social anxiety nose-spray drug stumbles in key trial, but safety holds up - Stock Titan Wed, 17 Dec 2025 08
- VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance hu, 13 Nov 2025 08
- ROSEN, LEADING TRIAL ATTORNEYS, Encourages Vistagen - GlobeNewswire Sat, 21 Feb 2026 00
- What To Expect From Vistagen Therapeutics Inc (VTGN) Q2 2026 Earnings - Yahoo Finance Wed, 12 Nov 2025 08
- Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026 (NASDAQ:VTGN) - Seeking Alpha ue, 18 Nov 2025 08
- Janus Henderson Just Took a 13.6% Stake in Vistagen. Should You Buy VTGN Stock Now? - Yahoo Finance Fri, 26 Sep 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4386 | 2468 | — | Stock Award(Grant) at price 0.56 per share. | PRINCE JOSHUA S | Chief Operating Officer | — | 2025-12-31 00:00:00 | D |
| 1 | 7541 | 12820 | — | Stock Award(Grant) at price 1.70 per share. | SINGH SHAWN K | Chief Executive Officer | — | 2025-06-30 00:00:00 | D |
| 2 | 7541 | 12820 | — | Stock Award(Grant) at price 1.70 per share. | ADLER REID G. | Officer | — | 2025-06-30 00:00:00 | D |
| 3 | 6617 | 11249 | — | Stock Award(Grant) at price 1.70 per share. | ANDERSON CYNTHIA LYNN | Chief Financial Officer | — | 2025-06-30 00:00:00 | D |
| 4 | 4882 | 8299 | — | Stock Award(Grant) at price 1.70 per share. | PRINCE JOSHUA S | Chief Operating Officer | — | 2025-06-30 00:00:00 | D |
| 5 | 2592 | 6499 | — | Stock Award(Grant) at price 2.51 per share. | ANDERSON CYNTHIA LYNN | Chief Financial Officer | — | 2024-12-31 00:00:00 | D |
| 6 | 3310 | 8300 | — | Stock Award(Grant) at price 2.51 per share. | PRINCE JOSHUA S | Chief Operating Officer | — | 2024-12-31 00:00:00 | D |
| 7 | 4854 | 14358 | — | Stock Award(Grant) at price 2.96 per share. | SINGH SHAWN K | Chief Executive Officer | — | 2024-06-28 00:00:00 | D |
| 8 | 4854 | 14358 | — | Stock Award(Grant) at price 2.96 per share. | ADLER REID G. | General Counsel | — | 2024-06-28 00:00:00 | D |
| 9 | 3592 | 10625 | — | Stock Award(Grant) at price 2.96 per share. | ANDERSON CYNTHIA LYNN | Chief Financial Officer | — | 2024-06-28 00:00:00 | D |
Financials
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | -278.40 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -55.34M | -32.45M | -58.74M | -46.82M |
| TotalUnusualItems | 0.00 | -232.00K | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -232.00K | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -51.42M | -29.36M | -59.25M | -47.76M |
| ReconciledDepreciation | 635.00K | 568.00K | 532.00K | 711.10K |
| EBITDA | -55.34M | -32.45M | -58.74M | -47.05M |
| EBIT | -55.97M | -33.02M | -59.27M | -47.76M |
| NetInterestIncome | 4.56M | 3.35M | 26.00K | 20.00K |
| InterestExpense | 23.00K | 0.00 | 13.00K | |
| InterestIncome | 4.56M | 3.35M | 49.00K | 20.00K |
| NormalizedIncome | -51.42M | -29.36M | -59.25M | -47.53M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -51.42M | -29.36M | -59.25M | -47.76M |
| TotalExpenses | 56.46M | 34.09M | 59.04M | 48.66M |
| RentExpenseSupplemental | 419.00K | 377.00K | 354.00K | |
| TotalOperatingIncomeAsReported | -55.97M | -33.02M | -59.27M | -47.78M |
| DilutedAverageShares | 30.88M | 19.35M | 6.96M | 6.60M |
| BasicAverageShares | 30.88M | 19.35M | 6.96M | 6.60M |
| DilutedEPS | -1.67 | -1.52 | -8.51 | -7.38 |
| BasicEPS | -1.67 | -1.52 | -8.51 | -7.38 |
| DilutedNIAvailtoComStockholders | -51.42M | -29.36M | -59.25M | -48.71M |
| NetIncomeCommonStockholders | -51.42M | -29.36M | -59.25M | -48.71M |
| PreferredStockDividends | 945.10K | 24.39M | ||
| NetIncome | -51.42M | -29.36M | -59.25M | -47.76M |
| NetIncomeIncludingNoncontrollingInterests | -51.42M | -29.36M | -59.25M | -47.76M |
| NetIncomeContinuousOperations | -51.42M | -29.36M | -59.25M | -47.76M |
| TaxProvision | 7.00K | 4.00K | 6.00K | 3.40K |
| PretaxIncome | -51.41M | -29.36M | -59.24M | -47.76M |
| OtherIncomeExpense | 5.00K | 312.00K | -232.00K | 600.00 |
| OtherNonOperatingIncomeExpenses | 5.00K | 312.00K | 600.00 | |
| SpecialIncomeCharges | 0.00 | -232.00K | 0.00 | |
| WriteOff | 0.00 | 232.00K | 0.00 | |
| NetNonOperatingInterestIncomeExpense | 4.56M | 3.35M | 26.00K | 20.00K |
| TotalOtherFinanceCost | -3.35M | -26.00K | ||
| InterestExpenseNonOperating | 23.00K | 0.00 | 13.00K | |
| InterestIncomeNonOperating | 4.56M | 3.35M | 49.00K | 20.00K |
| OperatingIncome | -55.97M | -33.02M | -59.27M | -47.55M |
| OperatingExpense | 56.46M | 34.09M | 59.04M | 48.66M |
| ResearchAndDevelopment | 39.38M | 20.02M | 44.38M | 35.41M |
| SellingGeneralAndAdministration | 17.08M | 14.06M | 14.66M | 13.25M |
| SellingAndMarketingExpense | 1.90M | 2.80M | 0.00 | |
| GeneralAndAdministrativeExpense | 17.08M | 14.06M | 14.66M | 10.45M |
| OtherGandA | 17.08M | 14.06M | 14.66M | 3.39M |
| InsuranceAndClaims | 1.38M | 578.00K | 449.00K | |
| RentAndLandingFees | 419.00K | 377.00K | 354.00K | |
| SalariesAndWages | 6.29M | 6.11M | 3.61M | |
| TotalRevenue | 486.00K | 1.06M | -227.00K | 1.11M |
| OperatingRevenue | 486.00K | 1.06M | -227.00K | 1.11M |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 4.52K | 4.52K | 4.52K | 4.52K |
| OrdinarySharesNumber | 29.00M | 27.03M | 7.31M | 6.88M |
| ShareIssued | 29.00M | 27.03M | 7.32M | 6.89M |
| TotalDebt | 1.51M | 2.12M | 2.71M | 3.04M |
| TangibleBookValue | 70.39M | 114.29M | 12.08M | 64.72M |
| InvestedCapital | 70.39M | 114.29M | 12.19M | 64.72M |
| WorkingCapital | 69.46M | 115.55M | 12.93M | 65.23M |
| NetTangibleAssets | 70.39M | 114.29M | 12.08M | 64.72M |
| CapitalLeaseObligations | 1.51M | 2.12M | 2.61M | 3.04M |
| CommonStockEquity | 70.39M | 114.29M | 12.08M | 64.72M |
| PreferredStockEquity | 4.30K | |||
| TotalCapitalization | 70.39M | 114.29M | 12.08M | 64.72M |
| TotalEquityGrossMinorityInterest | 70.39M | 114.29M | 12.08M | 64.72M |
| StockholdersEquity | 70.39M | 114.29M | 12.08M | 64.72M |
| GainsLossesNotAffectingRetainedEarnings | 5.00K | 0.00 | ||
| OtherEquityAdjustments | 5.00K | |||
| TreasuryStock | 3.97M | 3.97M | 3.97M | 3.97M |
| RetainedEarnings | -407.63M | -356.21M | -326.85M | -267.60M |
| AdditionalPaidInCapital | 481.96M | 474.44M | 342.89M | 336.28M |
| CapitalStock | 29.00K | 27.00K | 7.00K | 6.90K |
| CommonStock | 29.00K | 27.00K | 7.00K | 6.90K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 13.95M | 9.37M | 9.01M | 9.93M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.34M | 4.24M | 4.43M | 4.16M |
| NonCurrentAccruedExpenses | 6.27M | |||
| TradeandOtherPayablesNonCurrent | 0.00 | 6.27M | ||
| NonCurrentDeferredLiabilities | 391.00K | 2.67M | 2.31M | 1.56M |
| NonCurrentDeferredRevenue | 391.00K | 2.67M | 2.31M | 1.56M |
| LongTermDebtAndCapitalLeaseObligation | 948.00K | 1.57M | 2.12M | 2.61M |
| LongTermCapitalLeaseObligation | 948.00K | 1.57M | 2.12M | 2.61M |
| CurrentLiabilities | 12.61M | 5.12M | 4.57M | 5.77M |
| CurrentDeferredLiabilities | 2.59M | 791.00K | 714.00K | 1.24M |
| CurrentDeferredRevenue | 2.59M | 791.00K | 714.00K | 1.24M |
| CurrentDebtAndCapitalLeaseObligation | 561.00K | 550.00K | 591.00K | 433.30K |
| CurrentCapitalLeaseObligation | 561.00K | 550.00K | 486.00K | 433.30K |
| CurrentDebt | 105.00K | |||
| CurrentNotesPayable | 0.00 | 105.00K | 0.00 | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.36M | 1.62M | 337.00K | 66.20K |
| PayablesAndAccruedExpenses | 6.10M | 2.16M | 2.93M | 4.02M |
| CurrentAccruedExpenses | 5.45M | 616.00K | 459.00K | 1.26M |
| Payables | 653.00K | 1.55M | 2.47M | 2.76M |
| AccountsPayable | 653.00K | 1.55M | 2.47M | 2.76M |
| TotalAssets | 84.34M | 123.65M | 21.09M | 74.64M |
| TotalNonCurrentAssets | 2.27M | 2.98M | 3.58M | 3.65M |
| OtherNonCurrentAssets | 454.00K | 726.00K | ||
| NonCurrentPrepaidAssets | 101.00K | 101.00K | 100.90K | 47.80K |
| NonCurrentDeferredAssets | 625.00K | 714.00K | 468.20K | 529.00K |
| NetPPE | 1.81M | 2.25M | 2.77M | 3.08M |
| AccumulatedDepreciation | -1.40M | -1.25M | -1.19M | -1.27M |
| GrossPPE | 3.21M | 3.51M | 3.96M | 4.35M |
| Leases | 221.00K | 214.00K | 214.00K | 214.40K |
| OtherProperties | 2.88M | 3.27M | 3.71M | 4.05M |
| MachineryFurnitureEquipment | 113.00K | 22.00K | 40.00K | 76.20K |
| BuildingsAndImprovements | 3.22M | |||
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 82.08M | 120.67M | 17.51M | 71.00M |
| OtherCurrentAssets | 1.59M | 1.51M | 802.00K | 71.80K |
| CurrentDeferredAssets | 74.00K | 67.00K | 116.90K | 133.50K |
| PrepaidAssets | 2.34M | 808.70K | ||
| Receivables | 802.70K | 2.75M | 40.60K | |
| OtherReceivables | 802.70K | 2.75M | 40.60K | |
| CashCashEquivalentsAndShortTermInvestments | 80.48M | 119.17M | 16.64M | 68.14M |
| OtherShortTermInvestments | 13.35M | 0.00 | ||
| CashAndCashEquivalents | 67.13M | 119.17M | 16.64M | 68.14M |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| FreeCashFlow | -42.29M | -25.87M | -49.93M | -45.46M |
| RepurchaseOfCapitalStock | -174.00K | |||
| RepaymentOfDebt | 0.00 | -985.00K | -1.03M | -3.00K |
| IssuanceOfDebt | 0.00 | 224.40K | ||
| IssuanceOfCapitalStock | 3.01M | 129.38M | 104.00K | 4.44M |
| CapitalExpenditure | -191.00K | -61.00K | -212.00K | -200.40K |
| InterestPaidSupplementalData | 300.00 | 13.30K | ||
| IncomeTaxPaidSupplementalData | 3.40K | 2.60K | ||
| EndCashPosition | 67.13M | 119.17M | 16.64M | 68.14M |
| BeginningCashPosition | 119.17M | 16.64M | 68.14M | 103.11M |
| ChangesInCash | -52.03M | 102.53M | -51.50M | -34.97M |
| FinancingCashFlow | 3.21M | 128.40M | -1.04M | 10.48M |
| CashFlowFromContinuingFinancingActivities | 3.21M | 128.40M | -1.04M | 10.48M |
| ProceedsFromStockOptionExercised | 201.00K | 8.00K | 63.00K | 6.05M |
| NetCommonStockIssuance | 3.01M | 129.38M | -70.00K | 4.44M |
| CommonStockPayments | -174.00K | |||
| CommonStockIssuance | 3.01M | 129.38M | 104.00K | 4.44M |
| NetIssuancePaymentsOfDebt | 0.00 | -985.00K | -1.03M | -3.00K |
| NetShortTermDebtIssuance | 0.00 | -985.00K | -1.03M | 0.00 |
| ShortTermDebtPayments | 0.00 | -985.00K | -1.03M | 0.00 |
| ShortTermDebtIssuance | 224.40K | |||
| NetLongTermDebtIssuance | -1.50K | -3.00K | 221.10K | |
| LongTermDebtPayments | -1.50K | -3.00K | -3.30K | |
| LongTermDebtIssuance | 0.00 | 224.40K | ||
| InvestingCashFlow | -13.15M | -61.00K | -740.00K | -200.40K |
| CashFlowFromContinuingInvestingActivities | -13.15M | -61.00K | -740.00K | -200.40K |
| NetInvestmentPurchaseAndSale | -12.96M | 0.00 | ||
| SaleOfInvestment | 12.03M | 0.00 | ||
| PurchaseOfInvestment | -24.98M | 0.00 | ||
| NetBusinessPurchaseAndSale | 0.00 | -528.00K | 0.00 | |
| PurchaseOfBusiness | 0.00 | -528.00K | 0.00 | |
| NetPPEPurchaseAndSale | -191.00K | -61.00K | -212.00K | -200.40K |
| PurchaseOfPPE | -191.00K | -61.00K | -212.00K | -200.40K |
| OperatingCashFlow | -42.10M | -25.81M | -49.72M | -45.26M |
| CashFlowFromContinuingOperatingActivities | -42.10M | -25.81M | -49.72M | -45.26M |
| ChangeInWorkingCapital | 4.76M | 793.00K | 2.03M | -1.92M |
| ChangeInOtherWorkingCapital | -222.00K | 516.00K | 206.00K | -1.00M |
| ChangeInOtherCurrentLiabilities | -611.00K | -495.00K | -433.00K | -677.00K |
| ChangeInOtherCurrentAssets | 360.00K | |||
| ChangeInPayablesAndAccruedExpense | 5.68M | 522.00K | -934.00K | 1.69M |
| ChangeInPrepaidAssets | -88.00K | 250.00K | 3.19M | -1.92M |
| ChangeInReceivables | -40.60K | |||
| ChangesInAccountReceivables | -40.60K | |||
| OtherNonCashItems | 3.56M | |||
| StockBasedCompensation | 4.32M | 2.18M | 3.34M | 3.48M |
| AssetImpairmentCharge | 0.00 | 232.00K | 0.00 | |
| AmortizationOfSecurities | -389.00K | 0.00 | ||
| DepreciationAmortizationDepletion | 635.00K | 568.00K | 532.00K | 711.10K |
| DepreciationAndAmortization | 635.00K | 568.00K | 532.00K | 711.10K |
| Depreciation | 635.00K | 568.00K | 532.00K | 711.10K |
| OperatingGainsLosses | 6.00K | 78.00K | ||
| GainLossOnInvestmentSecurities | 78.00K | |||
| GainLossOnSaleOfPPE | 0.00 | 6.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -51.42M | -29.36M | -59.25M | -47.76M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for VTGN
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|